多西他赛联合顺铂治疗晚期非小细胞肺癌的临床观察  

Clinical study of combined chemotherapy of docetaxel plus cisplatin for advanced non-small cell lung cancer

作　　者：刘淑娟[1] 姚娟[1] 王琪琪[1] 阎磊[1] 

机构地区：[1]青岛市肿瘤医院内科,山东青岛226042

出　　处：《现代肿瘤医学》2008年第1期53-55,共3页Journal of Modern Oncology

摘　　要：目的:观察多西他赛联合顺铂方案对晚期非小细胞肺癌的疗效和毒副反应。方法:初治、晚期非小细胞肺癌75例,随机分为观察组和对照组。观察组40例,应用多西他赛联合顺铂化疗;对照组35例,应用异长春花碱联合顺铂化疗。观察两组疗效和毒副反应,2周期后评价疗效。结果:75例患者均可评价疗效,近期有效率分别为50%、42.9%,差异无统计学意义(P>0.05)。两组Ⅲ、Ⅳ度毒副反应均以骨髓抑制和消化道反应为主,其发生率无显著性差异(P>0.05)。观察组有2例患者出现严重体液潴留,未出现相关性死亡。结论:多西他赛联合顺铂化疗对晚期非小细胞肺癌有较好的疗效,但可致体液潴留,应用多西他赛时需强调化疗前激素的预处理、化疗后的病情监测和发生体液潴留时的处理。Objective： To investigate the efficacy, toxicity and side effects of combined chemotherapy of docetaxel plus cisplatin for patients with advanced NSCLC. Methods： Tptal of 75 patients with advanced NSCLC were enrolled into two groups. The DP group with 40 patients received docetaxel plus cisplatin and the NP group with 35 patients received vinorebine plus cisplatin. The side effects were evaluated . The efficacy was estimated after 2 cycles of chemotherapy. Results：The efficacy could be estimated in 75 patients. The overall response rate（ CB ＋ PB） was 50% in DP group and 42.9% in NP group. There was no significant statistical difference between the two groups. The major grade Ⅲ and Ⅳ toxicities were myelosuppression and gastrointestinal reactions in the two groups. 2 patients had severe fluid retention in DP group and there was no chemotherapy -related death. Conclusion： The combination chemotherapy of doeetaxel and cisplatin is effective in the treatment of advanced NSCLC. But doeetaxel may lead to fluid retention. Pretreatment of hormone before doeetaxel, careful observation and positive treatment should be emphasized.

关 键 词：非小细胞肺癌 多西他赛 异长春花碱 顺铂 联合化疗 

分 类 号：R734.2[医药卫生—肿瘤]